New Five-Year Agreement with the Alberta Sugar Beet Growers
MONTRÉAL and VANCOUVER, British Columbia, May 09, 2025 (GLOBE NEWSWIRE) — Rogers Sugar Inc. (the 'Corporation' or 'Rogers Sugar') (TSX: RSI) is pleased to announce a five-year agreement with the Alberta Sugar Beet Growers ('ASBG') for the supply of sugar beets to its Taber sugar refining plant. The new supply contract covers the 2025 to 2029 crops.
Established almost 75 years ago, the Taber operation — the only sugar beet processing facility in Canada — is supported by approximately 200 Southern Alberta farm families, which supply the refinery with sugar beets. As a result, all sugar produced at this location is 100% Canadian.
'We are pleased to have reached an agreement with the Alberta Sugar Beet Growers for another five years. This agreement will help support the needs of our customers in Western Canada,' stated Mike Walton, President and Chief Executive Officer of Lantic Inc and Rogers Sugar Inc.
About Rogers Sugar
Rogers is a corporation established under the laws of Canada. The Corporation holds all of the common shares of Lantic and its administrative office is in Montréal, Québec. Lantic operates cane sugar refineries in Montréal, Québec and Vancouver, British Columbia, as well as the only Canadian sugar beet processing facility in Taber, Alberta. Lantic also operate a distribution center in Toronto, Ontario. Lantic's sugar products are mainly marketed under the 'Lantic' trademark in Eastern Canada, and the 'Rogers' trademark in Western Canada and include granulated, icing, cube, yellow and brown sugars, liquid sugars, and specialty syrups. Lantic owns all of the common shares of TMTC and its head office is headquartered in Montréal, Québec. TMTC operates bottling plants in Granby, Dégelis and in St-Honoré-de-Shenley, Québec and in Websterville, Vermont. TMTC's products include maple syrup and derived maple syrup products supplied under retail private label brands in approximately fifty countries and sold under various brand names.
For more information about Rogers please visit our website at
www.LanticRogers.com.
For further information
Mr. Jean-Sébastien Couillard
Vice President of Finance, Chief Financial Officer and Corporate Secretary Phone: (514) 940-4350
Email:
jscouillard@lantic.ca
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Kovo+ Announces Management Change
Calgary, Alberta--(Newsfile Corp. - June 6, 2025) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") announces that Mark Detz has resigned as Chief Financial Officer of the Company, and Kovo accepted his resignation effective as of June 4, 2024. "As a core member of senior management, Mark has been an important member of our team, and we thank him for his contributions to the Company," said Justin Anderson, Chief Executive Officer of Kovo. Following a confidential recruitment process, the Company has identified and selected a candidate to succeed Mr. Detz as Chief Financial Offer and expects to announce the appointment in due course. About Kovo+ Holdings Inc. Kovo is a versatile technology company leading the charge in AI initiatives to drive impact and innovation across diverse industries. Kovo remains committed to its core business-model of strategic growth opportunities within mid-market Medical Billing firms, where exploitative business optimization synergies exist. Moving forward, Kovo will integrate accretive broader healthcare sector additions to its portfolio and opportunities beyond in multiple new markets. Dedicated to revolutionizing business process optimization through technological advancements and evolving AI-applied methods, Kovo embodies a commitment to ensured and enduring profitability. To learn more about Kovo and to keep up to date on Kovo news, visit Cautionary Note Regarding Forward-Looking Information Statements contained in this news release that are not historical facts are "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future and include, but are not limited to, (i) expectations regarding the Chief Financial Officer appointment; and (ii) expectations regarding the timing and appointment thereof. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as "anticipate", "proposed", "estimates", "would", "expects", "intends", "plans", "may", "will", and similar expressions. Forward-looking statements or information are based on a number of factors and assumptions that have been used to develop such statements and information, but which may prove to be incorrect. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. Although the Company believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. Contact Information For further information, please contact: investors@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Minsud Announces Option Grant
TSX-V: MSR TORONTO, June 6, 2025 /CNW/ - Minsud Resources Corp. (TSXV: MSR) ("Minsud" or the "Company") is pleased to announce that it has granted options to purchase an aggregate of 600,000 common shares of the Company (the "Stock Options") to certain directors of the Company. The Stock Options are exercisable at a price of $0.60 per share for a period of five years from the date of issuance. As of the date hereof, a total of 16,494,852 common shares of the Company are reserved for issuance under the Company's stock option plan and, after this new grant, 13,876,000 options will be outstanding. About Minsud Resources Corp. Minsud is a mineral exploration company focused on exploring its flagship Chita Valley Cu-Mo-Au-Ag-Pb-Zn Project, in the Province of San Juan, Argentina. The Company's shares are listed on the TSX-V under the trading symbol "MSR", and on the OTCQX under the symbol "MDSQF". Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Minsud Resources Corp. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Pharmaris Canada to Lead Sales and Marketing for Vimy Pharma Products Across Canada
TORONTO, ON / / June 6, 2025 / Two proudly Canadian pharmaceutical companies announced today a strategic partnership that reinforces their shared commitment to serving Canadian patients. Under the agreement, Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma product portfolio across Canada. This landmark collaboration unites two homegrown Canadian pharmaceutical organizations, both with deep roots in the Canadian healthcare landscape. The partnership exemplifies Canadian innovation and entrepreneurship in action, while strengthening domestic pharmaceutical capabilities and expertise. Built by Canadians for Canadians, both companies have demonstrated their dedication to advancing healthcare solutions that address the unique needs of the Canadian market. This alliance further cements their shared vision of making healthcare more accessible and affordable for patients from coast to coast. "Our partnership with Vimy Pharma marks a big step forward advancing access to critical medicines for Canadians,"said Michael Sine, President of Pharmaris. "This alliance demonstrates our shared commitment to putting Canadian patients first." "We are pleased to partner with Pharmaris in broadening access to essential medicines," stated Farris Smith, President of Vimy Pharma,"as we strive to improve outcomes and make a meaningful difference to patients." ABOUT PHARMARIS CANADA Pharmaris Canada is a pharmaceutical company committed to delivering high-quality healthcare products that support the well-being of Canadians. Pharmaris Canada is part of a large diversified global group based out of Vancouver, B.C started by two pharmacists. The group has business interests spanning pharmaceuticals, residential and commercial real estate, property development, hospitality, mobility solutions, and retail pharmacy operations. Pharmaris Canada offers a distinctive portfolio of over-the-counter (OTC) and generic pharmaceutical products. Our OTC range includes a Canadian-made line of iron supplements and a broad selection of German-manufactured effervescent vitamin tablets. As one of the few companies to successfully integrate branded OTC and generic medicines, Pharmaris has developed strong capabilities in brand management, prescription navigation, and market expansion. With a presence in 16 countries and a team of 585 employees, most of whom have been with the organization for over five years, Pharmaris continues to grow its global footprint through innovation and operational excellence. ABOUT VIMY PHARMA Vimy Pharma is a Canadian pharmaceutical company committed to ensuring a stable, reliable supply of essential medicines, reducing dependence on foreign sources, and supporting good-paying jobs for Canadians in life sciences and advanced manufacturing. Our products are made to the highest standards of quality and safety, meeting rigorous Health Canada guidelines. At Vimy Pharma, our team is inspired by the groundbreaking achievements of Drs. Frederick Banting and Charles Best, and James B. Collip whose discovery in Canada of insulin revolutionized treatments and changed millions of lives worldwide. Their spirit of ingenuity, collaboration, and commitment to public health continues to guide our approach as we develop and manufacture high-quality, affordable, essential medicines for Canadian health challenges. MEDIA CONTACTMichael SinePresident, Pharmaris Canadamichael@ Farris SmithFounder & President, Vimy Pharmaceuticals - 30 - SOURCE: Pharmaris View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
